Please provide your email address to receive an email when new articles are posted on . Phase 1 pharmacokinetics results showed comparability between SB17 and ustekinumab. Phase 3 results of SB17 will ...
July 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex ...